TIL Instil Bio, Inc. Stock Quote

TIL [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	31.70%	Shs Outstand	128.74M	Perf Week	9.25%
Market Cap	2.19B	Forward P/E	-	EPS next Y	-1.38	Insider Trans	3.03%	Shs Float	111.36M	Perf Month	10.10%
Income	-	PEG	-	EPS next Q	-0.20	Inst Own	55.80%	Short Float	3.03%	Perf Quarter	-
Sales	0.14M	P/S	15839.57	EPS this Y	-478.60%	Inst Trans	-	Short Ratio	8.16	Perf Half Y	-
Book/sh	5.17	P/B	3.29	EPS next Y	-9.60%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	4.74	P/C	3.59	EPS next 5Y	-	ROE	-	52W Range	14.42 - 29.49	Perf YTD	-35.70%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	85.30%	52W High	-42.35%	Beta	-
Dividend %	-	Quick Ratio	35.40	Sales past 5Y	-	Gross Margin	-	52W Low	17.89%	ATR	1.59
Employees	150	Current Ratio	35.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.60	Volatility	8.69% 10.08%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.78	Prev Close	16.75
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	413.16K	Price	17.00
Recom	2.00	SMA20	-1.11%	SMA50	-9.44%	SMA200	-13.84%	Volume	323,991	Change	1.49%

Apr-13-21

Initiated

Truist

Buy

$32

Apr-13-21

Initiated

Morgan Stanley

Equal-Weight

$24

Apr-13-21

Initiated

Cowen

Outperform

Jun-01-21 07:00AM	Instil Bio to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-13-21 07:00AM	Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire +5.83%
Apr-29-21 08:45AM	At a Recent Cancer Research Conference, Instil Bio Stole the Show Motley Fool +6.10%
Apr-27-21 07:00AM	Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma GlobeNewswire
Apr-12-21 07:18AM	Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-23-21 05:00PM	Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-19-21 04:25PM	Three Biotechs, plus a Marijuana Lender, Open for Trading Barrons.com
Mar-18-21 08:26PM	Instil Bio Announces Pricing of Upsized Initial Public Offering GlobeNewswire

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McGaughy R Kent Jr	Director	Mar 23	Buy	20.00	450,000	9,000,000	8,478,790	Mar 25 05:28 PM
Vivo Capital IX, LLC	10% Owner	Mar 23	Buy	20.00	300,000	6,000,000	12,486,787	Mar 25 05:32 PM
Crouch Bronson	CEO and Chairman	Mar 23	Buy	20.00	450,000	9,000,000	37,980,073	Mar 25 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience